TXG (10x Genomics) Shareholder Yield % : -0.01% (As of Mar. 2026)


TXG 10x Genomics Inc TXG
62 GF Score
Price $39.19
GF Value $18.98
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is 10x Genomics Shareholder Yield %?

10x Genomics TXG +2.22% 62 Shareholder Yield % is -0.01% as of Mar. 2026. GuruFocus rates TXG with a GF Score™ of 62/100 and a GF Value™ of $18.98 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 654 Healthcare Providers & Services companies, 10x Genomics ranks worse than 51.53% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, 10x Genomics's Shareholder Yield % was -0.01%.


10x Genomics  (NAS:TXG) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


10x Genomics Shareholder Yield % Related Terms


10x Genomics Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for 10x Genomics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

10x Genomics Shareholder Yield % Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only -0.09 -0.51 -0.01 0.65 0.14

10x Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.11 0.70 0.45 0.14 -0.01

TXG vs DOCS, WAY, PRVA: Shareholder Yield % Comparison

For the Health Information Services subindustry, 10x Genomics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


10x Genomics Shareholder Yield % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where 10x Genomics's Shareholder Yield % falls into.


TXG
62GF Score
10x Genomics Inc TXG
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

10x Genomics Shareholder Yield % Calculation

10x Genomics's Shareholder Yield % for the quarter that ended in Mar. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+0.00 %+-0.01 %
=-0.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -0.01% mean?
10x Genomics (TXG) has a Shareholder Yield % of -0.01% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on 10x Genomics and its competitors. According to the industry distribution chart, 10x Genomics ranks #337 out of 654 companies in the Healthcare Providers & Services industry, placing it in the top 51.5%.
Is 10x Genomics' Shareholder Yield % too high?
10x Genomics' current Shareholder Yield % is -0.01%. Based on the distribution chart, 10x Genomics ranks #337 out of 654 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, 10x Genomics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Shareholder Yield % compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #337 out of 654 companies for Shareholder Yield %. This places 10x Genomics in the lower half of its industry. The industry median Shareholder Yield % is 0.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Healthcare Providers & Services company?
The median Shareholder Yield % among Healthcare Providers & Services companies is 0.08, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Shareholder Yield % is 0.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Shareholder Yield % is -0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.98, compared to a current price of $39.19 — trading 106.5% above its estimated fair value. The current Shareholder Yield % is -0.01%. 10x Genomics' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For 10x Genomics (TXG), the current Shareholder Yield % is -0.01% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 10x Genomics (TXG) Overvalued in 2026?

Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued. The current stock price of $39.19 is trading 106.5% above its estimated GF Value™ of $18.98. GuruFocus considers 10x Genomics to be Significantly Overvalued.

Key valuation signals for TXG:

  • Shareholder Yield %: -0.01%
  • GF Value™: $18.98 vs. price of $39.19 (106.5% above fair value)
  • GF Score™: 62/100 with 8 warning signs

No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


10x Genomics Business Description

Other Exchanges 0A88:UK1KJ:Germany
Address 6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
62GF Score

Get the complete analysis for TXG

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.19
Price
$18.98
GF Value